Tumor immunotherapy is only effective in a fraction of patients due to a low response rate
and severe side effects, and these challenges of immunotherapy in clinics can be addressed …

Therapeutic targeting of the immune system in cancer is now a clinical reality and marked
successes have been achieved, most notably through the use of checkpoint blockade …

Nutritional metal ions play critical roles in many important immune processes. Hence, the
effective modulation of metal ions may open up new forms of immunotherapy, termed as …

DNA derived from chemotherapeutics-killed tumor cells is one of the most important damage-
associated molecular patterns that can activate the cGAS-STING (cyclic GMP-AMP synthase …

Current cancer immunotherapy [eg, immune checkpoint blockade (ICB)] only benefits small
subsets of patients, largely due to immunosuppressive tumor microenvironment (TME). In …

Cancer immunotherapy is revolutionizing oncology. However, dose-limiting toxicities and
low patient response rates remain major challenges in the clinic. Cancer nanomedicine in …

In situ cancer vaccination refers to any approach that exploits tumour antigens available at a
tumour site to induce tumour-specific adaptive immune responses. These approaches hold …

Cancer immunotherapies that train or stimulate the inherent immunological systems to
recognize, attack, and eradicate tumor cells with minimal damage to healthy cells have …

Although notable progress has been made on novel cancer treatments, the overall survival
rate and therapeutic effects are still unsatisfactory for cancer patients …

Cancer vaccines aim at eliciting tumor‐specific responses for the immune system to identify
and eradicate malignant tumor cells while sparing the normal tissues. Furthermore, cancer …